Skip to main content
Main analysis: Pluri in 2025: Commercialization Has Started, but 2026 Is Still an EIB Bridge Year
BySeptember 17, 2025~10 min read

Pluri: Weinstein, Kokomodo, and How a Funding Move Also Becomes a Control Move

In 2025, Pluri tied together Weinstein’s financing, his board entry, the Kokomodo acquisition from entities he controlled, and only later the governance cure around the audit committee. That does not amount to formal control, but it does show how a funding move can also reshape influence over capital allocation.

CompanyPluri

Not Just a Footnote to the Main Article

The main article already framed 2025 at Pluri as a financing year first. This follow-up isolates a different thread: how that same financing thread also reshaped influence around the board and capital allocation. Not control in the formal sense of majority ownership. Control in the softer sense of who sits around the table, who provides the money, and who also sells the company a strategic asset along the way.

That matters because four events that look separate at first glance, the January private placement, Weinstein’s February board entry, the April acquisition of roughly 79% of Kokomodo, and the September governance cure around the audit committee, read in the filings like a single arc. Capital, dealmaking, and governance did not move on separate tracks here.

The filings also do not say that Weinstein holds formal control over the company, and this piece does not make that claim. What they do show is something narrower and more important: Pluri brought in capital from a strategic investor, committed to give him a board seat, then completed a share-based acquisition from entities he controlled of an asset whose current contribution to results was still not material. Only after that, once the committee structure weakened, did the governance repair arrive through the appointment of Eitan Ajchenbaum.

DateWhat happenedCapital layerGovernance layer
January 23, 2025Weinstein investment agreement was signed1,383,948 shares, 26,030 pre-funded warrants, and 84,599 warrants at $4.61 per unitThe company agreed to appoint Weinstein to the board upon closing
January 23, 2025Kokomodo term sheet was also signed976,139 Pluri shares were set as deal considerationThe same influence circle linked the financing and the asset sale
April 25, 2025The investment agreement was amended976,139 common shares were exchanged for additional pre-funded warrantsThe equity layer was reworked right before the acquisition closed
April 28, 2025The Kokomodo acquisition closed976,139 shares were issued to entities controlled by Weinstein, plus assignment of a $0.5 million convertible loanA strategic asset deal closed with a party already sitting close to the table
June 30, 2025Doron Birger was not re-electedShareholder approval activated the instrument layer of the investmentThe audit committee fell to only two independent directors
September 10 to 11, 2025Ajchenbaum was appointed and Nasdaq closed the matterNo new capital came inAudit committee compliance was restored and a finance oversight anchor was rebuilt
The same share count appears twice on the same thread

When the Financing and the Acquisition Sit in the Same Sentence

The first thing that stands out is timing. On January 23, 2025, Pluri signed the investment agreement with a company owned by Weinstein, and on that same day it also signed the term sheet to acquire roughly 79% of Kokomodo. That is already more than random chronology. It is a structure in which the strategic investor arrives both as financier and as a party around a strategic acquisition.

The second detail is even stronger. In the equity note, the company says the Weinstein investment included 1,383,948 common shares, pre-funded warrants to buy 26,030 shares, and warrants to buy 84,599 shares. The price was $4.61 per share and accompanying warrant, and the offering closed on February 5 with gross proceeds of $6.5 million and $420 thousand of issuance expenses. But the same note also says, explicitly, that Weinstein’s board appointment became effective upon the closing of the offering, and that the company agreed to continue recommending his election so long as the investor continued to hold at least 10% of its issued and outstanding common shares.

That is the heart of the story. The money did not arrive by itself. It arrived with a board seat, and with a mechanism that tied economic ownership to continued presence around the board table.

Another non-obvious point is the sequencing between capital and governance. The pre-funded warrants and common warrants were subject to shareholder approval, and they carried a 19.99% beneficial ownership cap until that approval was received on June 30, 2025. In other words, part of the capital structure remained constrained until the end of June. The board seat did not wait. It became effective upon closing in February. That matters because it shows governance influence arriving before the full flexibility of the equity-linked instrument package was unlocked.

The symmetry between the financing and the Kokomodo deal becomes even sharper at the end of April. On April 25, Pluri amended the investment agreement and exchanged 976,139 common shares for additional pre-funded warrants covering that exact same number of shares. Three days later, on April 28, it closed the Kokomodo acquisition in exchange for 976,139 shares issued to entities controlled by Weinstein, together with the assignment of a $0.5 million convertible loan.

The filings do not explicitly say that this was a coordinated move designed to free up those shares for the Kokomodo deal, so it would be wrong to present that as a stated fact. But the overlap in counterparty identity, dates, and share count is so tight that it is hard to read the two moves as truly separate. It is the same capital thread, with two destinations: bringing cash in, and bringing an asset in.

What Pluri Actually Bought

To see whether this was a clean operating expansion or also a reallocation of influence, you have to look at what was actually acquired. In the Kokomodo note, Pluri says the term sheet consideration was $4.5 million in shares, and that as of the signing date those 976,139 consideration shares represented 12.14% of Pluri’s fully diluted share capital, even before taking into account the securities issued on the same day under the Weinstein investment agreement. That figure matters because it shows that the asset leg of the transaction was already large enough on its own to touch the influence question, even before layering the financing package on top.

The second step is asset quality. Pluri says the results of Kokomodo included from the acquisition date were not material to the consolidated financial statements, and that no pro forma information was presented because the acquisition had an immaterial effect on the statement of operations. At the same time, the purchase price allocation shows $2.823 million of intangible assets, $3.136 million of goodwill, and $2.714 million of net assets acquired, against $1.164 million of non-controlling interests.

Purchase price allocation item$ million
Net assets acquired2.714
Intangible assets2.823
Goodwill3.136
Non-controlling interest-1.164
Purchase price4.686

The analytical point is straightforward. Pluri did not use its shares to acquire a current earnings engine that already changes the numbers. It used its shares to acquire an early-stage strategic asset, with a large goodwill and intangible asset component, from within the same capital circle that had already invested in the company and entered the boardroom.

There is, of course, a reasonable bullish read as well: if Weinstein is bringing in money, taking a board seat, and transferring in an asset he believes in, maybe that is evidence of deeper commitment. That is a legitimate counter-read. But it misses the more important question. In a company that still depends on equity markets, a move like this is not only portfolio expansion. It also determines who shapes the next capital allocation decision, and in what structure.

One more point should not be missed. In the same corporate governance section where Pluri lists its directors, it also says the board determined that Weinstein qualifies as an independent director under SEC and Nasdaq rules. That is formal independence, and the company is entitled to rely on it. But formal independence does not erase the simpler economic fact: the same person came in as an investor, received a board seat, and was also tied to an asset transaction paid for in stock. Regulatory distance is not the same thing as strategic distance.

The Governance Cure Arrived Only at the End

This is where the fourth leg of the chain comes in. On June 30, 2025, following the annual meeting results, Doron Birger was not re-elected. Birger had been the chairman of the audit committee and the sole member of the investment committee. The consequence was not just a personnel change. Between June 30 and September 10, 2025, the audit committee consisted of only two independent directors, leaving the company out of compliance with the Nasdaq rule that requires at least three independent directors on that committee.

That looks like a governance footnote, but it sits right on the pressure point of the story. The audit committee is where reporting discipline and financial oversight live. The investment committee, under the same Item 10 disclosure, oversees the investment portfolio, hedging policies, foreign-exchange exposures, and periodic cash flow monitoring. In other words, in the same year when financing, dilution, and a strategic acquisition became intertwined, the financial oversight layer weakened.

Audit committee composition across the event chain

On September 10, Ajchenbaum was appointed to the board, to the audit committee, and as its chairman, and was also designated as an audit committee financial expert. On that same day he was appointed as the sole member of the investment committee. On September 11, Nasdaq notified the company that it had regained compliance and the matter was closed.

That is an important repair. It should not be dismissed. Ajchenbaum brings deep experience in finance, risk, controls, and reporting. Even so, the timing matters. The fix did not arrive before the influence expansion. It arrived after it. First came the financing tied to a board seat. Then came the asset deal from the same circle. Only after the committee structure weakened did the independent financial oversight layer get rebuilt.

From an analytical perspective, that means the cure does not erase the governance question. It sharpens it. If 2025 remains a one-off year, the story may read as a dense but manageable sequence of events. If the next year brings more equity-heavy strategic moves around the same influence axis, it will become much harder to treat this as coincidence.

What the Market Should Measure Now

The bottom line of this continuation is simple: in 2025, Pluri did not just raise money. It also redrew, through that same move, the map of influence around capital allocation. Weinstein’s financing, his board seat, the Kokomodo acquisition from entities he controlled, and then the later need to repair the oversight layer through Ajchenbaum’s appointment are not four different stories. They are one story.

What needs to be watched from here?

  • Whether Weinstein continues to hold the level of ownership that keeps economic ownership tied to ongoing board standing.
  • Whether future strategic moves, if they come, continue to be executed mainly through stock and equity-linked dilution or on a cleaner cash basis.
  • Whether the audit committee and investment committee under Ajchenbaum start to produce sharper disclosure and clearer discipline around financing and capital allocation decisions.

If those three points develop well, 2025 may eventually read as the year Pluri brought in a strategic investor who expanded both capability and oversight. If not, 2025 may look, in hindsight, like the year Pluri combined financing with an influence shift well before the underlying operating economics were mature enough to carry that comfortably.

Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.

The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.

The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.

Found an issue in this analysis?Editorial corrections and sharp feedback help keep the coverage honest.
Report a correction